65,437 trials
Cytokine Release Syndrome · COVID19
Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L
Body Fat Disorder
Primary: Rate of Device- or Procedure-related Adverse Events — 1 device-or procedure-related AEs
Chronic Kidney Diseases · Hyperkalemia
Primary: Change in Fasting Serum Potassium Concentrations — -0.2 mg/dL
Non-Transitional Cell Carcinoma of the Urothelial Tract · Small Cell of the Bladder · Adenocarcinoma of the Bladder
Primary: Overall Response Rate — 2; 11; 2 Participants
Acne Vulgaris
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 38.5; 11.5 percentage of participants
Atrophic Vaginitis
Primary: Vaginal Cytology — 29; 19; 0 participants
Meniscus Tear, Tibial · Pain, Postoperative · Postoperative Complications
Primary: Pain Levels Recorded With a Visual Analogue Scale — 25.6; 28.8 score on a scale
Headache
Primary: Headache Days — 7.2; 4.2; 1.6 days/month — p=0.056
Post-traumatic Headache
Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079
Breast Cancer
Primary: Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs) — 33.3; 50.0 Percentage of participants — p==0.0941
Neurofibromatosis Type 2 · Vestibular Schwannomas
Primary: Expression Levels of p-S6 Based Immunohistochemistry (Histoscore) — 90 score
Complicated Urinary Tract Infection · Pyelonephritis
Primary: Number of Participants With ≥1 Adverse Events (AEs) — 59; 20 Participants
Lymphoma
Primary: Progression-free Survival at 36 Months — 93.1; 89.7 percentage of participants — p=0.9669
Wrinkles
Primary: Assessment of Wrinkle Severity Using the Lemperle Wrinkle Assessment Scale — 3.31; 2.45 Score on a Scale — p=<0.01
Clinical High Risk for Psychosis
Primary: Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 — 0.40684405; -0.081559; 0.0219668; -0.0269017 Percent change